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ABSTRACT 
DNA mismatch repair (MMR) deficiency has been associated with a higher risk of developing 
colorectal, endometrial, and ovarian cancer, and confers resistance in conventional 
chemotherapy. In addition to the lack of treatment options that work efficaciously on these 
MMR-deficient cancer patients, there is a great need to discover new drug leads for this 
purpose. In this study, we screened through a library of commercial and semisynthetic natural 
compounds to identify potential synthetic lethal drugs that may selectively target MLH1 
mutants using MLH1 isogenic colorectal cancer cell lines and various cancer cell lines with 
known MLH1 status. We identified a novel diarylpentanoid analogue, 2-benzoyl-6-(2,3-
dimethoxybenzylidene)-cyclohexenol, coded as AS13, that demonstrated selective toxicity 
toward MLH1-deficient cancer cells. Subsequent analysis suggested AS13 induced elevated 
levels of oxidative stress, resulting in DNA damage where only the proficient MLH1 cells were 
able to be repaired and hence escaping cellular death. While AS13 is modest in potency and 
selectivity, this discovery has the potential to lead to further drug development that may offer 
better treatment options for cancer patients with MLH1 deficiency.  
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